Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
Main finding · PFS, GC exposure (time-varying Cox model)Result — go to the resultAdjusted hazard ratio 2.64 95% CI 0.36–19.61Authors' conclusion
In this prospective ICI-IA cohort, low doses of glucocorticoids (median dose 13 mg [IQR: 7.5, 25] in the first month of treatment) did not adversely affect PFS.
Study context
- Population
- Patients with cancer with immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA), RADIOS registry; mean age 64.85 years, 48.3% female, 32% melanoma, 56.4% stage IV
- Participants
- 269 patients
- Exposure
- GC exposure vs no GC / lower dose
- Outcome
- Cancer progression-free survival (PFS)
Methodological detailsmulticentre, registry, time-varying and landmark multivariable Cox regression
- Multicentre
- Registry
- Time-varying and landmark multivariable Cox regression
Main finding
PFS, GC exposure (time-varying Cox model)
Adjusted hazard ratio
2.64
95% CI 0.36–19.61
Glucocorticoids
aHR 2.64 (95% CI 0.36–19.61)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| PFS, GC dose abovevs below median in first month · first month of ICI-IA treatmentAdjusted Cox models; not associated with worse PFS | 1.15 (0.59–2.25) | |
| 0.512Adjusted hazard ratio (log scale) |
Cancer progression (all participants)
- Cancer progression
- 67 (24.9%)
GC dose in first month (prednisone equivalent) · first month of treatment
- Median GC dose, mg daily
- 13
- IQR
- 7.5, 25
- Received immunomodulatory DMARD
- 7.8%
Original publication
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Ann Rheum Dis. Published 10 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →